University of Central Florida Research Foundation Inc

Mannkind Corporation

Institut National De La Sante Et De La Recherche Medicale

Sanford Burnham Prebys Medical Discovery Institute

Friedrich Alexander University

Otto Phanstiel

John J Freeman

Kelly Sullivan Kraft

William Elliot Bay

Navneet Kaur

Paul Serwinski

Vincent Pavia

Aaron Muth

Paul M Hershberger

Patrick R Maloney

Jean-Michel Brunel

Satyamaheshwar Peddibhotla

Holly Moots

Jennifer J Archer

William Elliott Bay

Nuska Tschammer

Vinnie Pavia

Ken Teter

Various embodiments relate to compounds and methods useful for preventing or treating a cancer in a subject. The method may include administering to a subject a composition according to any of the embodiments described herein in an amount effective to inhibit metastatic activity or tumor growth in the subject.

Non-polyamine based polyamine transport inhibitors and their use in the treatment of human cancers

Disclosed embodiments relate to improved methods for the synthesis of activated fumarate intermediates and their use in chemical synthesis. Disclosed embodiments describe the synthesis of activated fumarate esters including those derived from activating groups including: 4-nitrophenyl, diphenylphophoryl azide, pivaloyl chloride, chlorosulfonyl isocyanate, p-nitrophenol, MEF, trifluoroacetyl and chlorine, for example, ethyl fumaroyl chloride and the subsequent use of the activated ester in situ. Further embodiments describe the improved synthesis of substituted aminoalkyl-diketopiperazines from unisolated and unpurified intermediates allowing for improved yields and reactor throughput.

Methods for the synthesis of activated ethylfumarates and their use as intermediates

A method for the synthesis of N-protected 3,6-aminoalkyl-2,5-diketopiperazines is provided. The method includes obtaining a cyclic α-N protected active amino ester and adding it to a mixture of an amine catalyst in an organic solvent.

Formation of N-protected 3,6-bis-(4-aminobutyl)-2,5-diketopiperazine through a cyclic alpha-N-protected amino ester

Anthranilic acid derivatives and their use in the treatment of human cancers

Motuporamine agents having antimicrobial activity and uses thereof.

Motuporamine derivatives as antimicrobial agents and antibiotic enhancers against resistant gram-negative bacteria

A method for the synthesis of N-protected 3,6-aminoalkyl-2,5-diketopiperazines is provided. The method includes obtaining a cyclic &#x3b1;-N protected active amino ester and adding it to a mixture of an amine catalyst in an organic solvent.

Formation of N-protected 3,6-bis-(4-aminobutyl)-2,5-diketopiperazine through a cyclic &#x3b1;-N-protected amino ester

Formation of N-protected 3,6-bis-(4-aminobutyl)-2,5-diketopiperazine through a cyclic alpha-N-protected amino ester intermediate

Disclosed herein are novel motuporamine compounds that act as anti-metastatic agents with low toxicity and high anti-migration activity. The non-toxic, anti-metastatic agents may be given to patients with potential or actual metastatic cancers, such as pancreatic cancers, alone in combination with known and/or new therapies to help block the growth and spread of tumor(s).

Anti-metastatic agents predicated upon polyamine macrocylic conjugates

Formation of N-protected bis-3,6-(4-aminobutyl)-2, 5-diketopiperazine through a cyclic alpha-N-protected amino ester

Disclosed herein are di-substituted aryl polyamine compounds and methods of making and using the same. The di-substituted polyamine compounds act as PTS targeting agents, which selectively target the polyamine transport system (PTS) with high efficacy and have improved stability in the presence of amine oxidases.

Polyamine transport selective therapeutic agents with enhanced stability

Growing community of inventors

Oviedo, FL, United States of America

Otto Phanstiel